Wednesday, October 4, 2023
Wednesday, October 4, 2023

Contact: 561.316.3330

CareINSIGHTS.ai Introduced: 1st of Its Kind Clinical Intervention Program Powered by AI-based Predictive Modeling

CareINSIGHTS.ai was introduced today by Renalogic. CareINSIGHTS.ai is the first of its kind, clinical intervention program that is powered by AI-based predictive modeling, and is proven to help bend the catastrophic claims cost curve.

CareINSIGHTS.ai is the industry’s most advanced kidney care management program combining intelligence with tailored intervention to reduce the associated risk.

“We’re putting an end to surprise dialysis claims and changing the prognosis while reducing the hidden risk associated with CKD,” Mark Masson, President at Renalogic said. “The shift to identifying previously hidden risk results in a new, higher standard of chronic condition management. Today, we are identifying future CKD risk earlier than anyone else. CareINSIGHTS.ai can accurately predict when individuals will progress to higher acuity stages of chronic kidney disease and when they will progress to dialysis without proper intervention. This enables us to control future risk and provide the right care at the right time. We are helping to avoid growing claims costs associated with CKD and dialysis.”

CareINSIGHTS.ai arrives at a time when CKD continues to be the third-highest medical claims cost category. In 2020, estimated claims cost associated with CKD, which is often referred to as “the silent epidemic,” will total over $100 billion for commercial health plans. With new predictive modeling and AI, using hundreds of dimensions of data, CareINSIGHTS.ai can accurately predict each plan member’s propensity to advance to the next stage of CKD, including dialysis within the next 12 months. That’s every member, even those without a CKD diagnosis. This makes it possible to avoid the risk associated with CKD and dialysis, by delivering personalized intervention based on much more than the member’s CKD stage, including their trajectory and expected progression toward dialysis.

For more than a decade, Renalogic has been using data to mitigate CKD and dialysis risk. Now, CareINSIGHTS.ai is the next evolution of predictive modeling powered by AI. CareINSIGHTS.ai reports with 90% accuracy in identifying where and when CKD and dialysis claims will appear in the future. Over time, the predictive modeling will improve as it continues to think and learn as a “doctor.”

CareINSIGHTS.ai gives health plan administrators a look into future healthcare claims costs and utilization. “When we know what’s coming, we have time to avoid an emergent start to dialysis,” Masson said. Renalogic, a pioneer in dialysis cost containment, is again leading the industry by adopting a modern, AI-driven approach. “By taking the guesswork out of hidden risk, we’re giving health plan fiduciaries an extraordinary advantage compared to other dialysis cost containment options. CareINSIGHTS.ai layers claims cost containment and cost avoidance. What’s more, the proprietary predictive intelligence indicates future plan needs and could present additional savings for plans year over year.”

The Renalogic* Kidney Dialysis Avoidance Program (KDAP) successfully slows, stops and even reverses the progression of CKD. Nearly 80% of active KDAP members who have participated for six months or more have maintained or improved their CKD disease state. CareINSIGHTS.ai identifies additional risk earlier, identifies gaps in care and the leading indicator for each member’s trajectory toward dialysis. This makes personalized intervention as unique as each member’s fingerprint a reality for Renalogic clients.

Renalogic notes: For nearly two decades, we continue to be proud, forward-thinking leaders in a niche industry that is in crisis. We are an ambitious disruptor driving positive change to contain the catastrophic costs of dialysis. We are changing the way plan administrators think about dialysis. Chronic Kidney Disease (CKD) costs are an epidemic issue that will not resolve on its own. The logical approach is to get ahead of the curve. We are one company, one cause, leading the industry by empowering our clients to avoid dialysis altogether with solutions and technology for kidney disease management. No one does what we do. We exist to open minds, achieve sustainable results for our clients and be an advocate for kidney disease management, dialysis cost containment and prevention.

SourceRenalogic
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Centinel Spine’s prodisc ® Continues to Change Lives After Over 30 Years and 250,000 Total Disc Replacement Implantations

The prodisc lumbar and cervical technologies will be highlighted by Centinel Spine at the upcoming 2023 annual EUROSPINE meeting and congress in Frankfurt, Germany (October 4-6, 2023). The prodisc technology portfolio now includes four cervical and two lumbar devices—5 approved by the FDA—and has been validated with a reported reoperation rate of less than 1%.

Amber Implants Announces Start of Clinical Trial with VCFix® Spinal System

This first-in-human clinical trial will assess the safety and effectiveness of the VCFix® Spinal System implant for patients suffering from vertebral compression fractures. The implant is provided with a user-friendly, single-use sterile surgical kit, ensuring perfect traceability and reducing the risk of infection. 

RaySearch Deepens Collaboration with P-Cure

The expanded collaboration will enable users of the P-Cure proton therapy system to use RayStation and RayCare in a seamlessly integrated environment. The P-Cure system is a gantry-less seated proton system, designed to fit within linac vaults, that has recently been cleared by the FDA. It is used clinically by the Hadassah Medical Center in Jerusalem – the only proton facility in the Middle East – to treat CNS, head and neck, thoracic and pancreatic malignancies.

Edinburgh-based Med-tech Firm in MBO to Expand Into New Markets and Technologies

The acquisition will enable Novarum to build on its strong lateral flow test customer base and extend into adjacent markets. 

Biomic Sciences Issues Voluntary Nationwide Recall of ION* Sinus Support, ION* Biome Sinus, and Restore Sinus Spray Products Due to Microbial Contamination

Risk Statement: In the population most at risk, patients or individuals who recently underwent nasal or sinus surgery, there is a reasonable probability that the use of the affected product could potentially result in severe or life-threatening adverse events such as bacteremia or fungemia, invasive bacterial or fungal rhinosinusitis, or disseminated fungal infection. To date, Biomic Sciences has not received any reports of adverse events related to this product.

By using this website you agree to accept Medical Device News Magazine Privacy Policy